Zilebesiran: A Novel RNA Interference Therapeutic for Hypertension

Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality, yet blood pressure control rates are suboptimal, partly due to adherence challenges with daily medications. Zilebesiran is an investigational small interfering RNA therapy targeting hepatic angiotensinogen synthesis to achieve prolonged suppression of the renin-angiotensin-aldosterone system. By conjugating the small interfering RNA to N-acetylgalactosamine, zilebesiran is delivered specifically to hepatocytes, leading to >90% reductions in circulating angiotensinogen and consequently lower angiotensin II levels. Early-phase clinical trials have demonstrated dose-dependent, sustained blood pressure reductions with zilebesiran. In a phase 1 trial, single subcutaneous doses ≥200 mg produced clinically significant declines in 24-hour ambulatory systolic/diastolic blood pressure (mean reductions >10/5 mm Hg) within 8 weeks, with effects persisting for up to 6 months. A subsequent phase 2 trial (EKG Anywhere Anytime-1) confirmed that quarterly or biannual zilebesiran dosing can achieve 24-hour systolic blood pressure reductions on the order of 10-15 mm Hg versus placebo at 3 months (P < 0.001). Zilebesiran has been well tolerated to date, with mild injection-site reactions and occasional transient mild hyperkalemia as the primary adverse effects. No serious hypotension or renal impairment attributable to renin-angiotensin-aldosterone system suppression has been observed in short-term studies. Therapeutic applications under investigation include use as monotherapy in patients with essential hypertension and as an adjunct for patients with resistant hypertension or high cardiovascular risk. This manuscript provides a comprehensive overview of zilebesiran's mechanism of action, pharmacokinetics/pharmacodynamics, clinical trial evidence, potential role in hypertension management and related conditions, as well as its safety and tolerability profile, based on current peer-reviewed data.